Business Briefs

Company news: Auxilium and GSK; J&J's Janssen

May 22, 2012

Auxilium inked a co-promote deal with GSK on its Testim 1% testosterone gel for the US.
 

Company news: Novo Nordisk and Health Union

May 21, 2012

Novo Nordisk expanded its motorsports initiative, while online firm Health Union launched a mobile app designed to help patients monitor migraines.
 

Company news: Haymarket Medical, Johnson & Johnson

May 17, 2012

Hitting the 1,000-download mark in less than a week, Haymarket Medical said its new myCME app has been an iTunes top 10 US medical app ever since.
 

Company news: Pfizer, OraSure

May 16, 2012

The FDA panel's tepid embrace of Pfizer's RA drug tofacitinib last week has been matched by an equally anemic payer reaction.
 

Company news: Digital health edition

May 15, 2012

Physician social network adoption was flat from 2011-2012, a survey says, and Everyday Health gets a nom for a daytime Emmy
 

Company news: two drugs clear FDA panel

May 14, 2012

FDA panel votes for second weight loss drug this year, Gilead's HIV treatment gets panel nod
 

Company news: Pfizer, Orexigen

May 10, 2012

Reports that Pfizer is pulling out of the Lipitor business are somewhat premature, spokesperson MacKay Jimeson told MM&M.
 

Company news: GlaxoSmithKline, Teva

May 09, 2012

GlaxoSmithKline is once again in hot pursuit of Human Genome Sciences. The company is back with the same $2.6 billion bid, but this time rather than asking HGSI to join GSK the Britain-based firm is offering $13 a share in cash. Meanwhile, Teva reported first quarter sales hit $5B.
 

Company news: Pfizer, Sanofi

May 08, 2012

For anyone who thought Pfizer's RA candidate tofacitinib would sail through its review tomorrow with an FDA advisory committee, documents released ahead of the meeting indicate the devil's in the details.
 

Company news: Abbott, Vertex

May 07, 2012

Abbott settled a massive federal and state lawsuit over off-label marketing of Depakote to the tune of $1.5 billion and a token guilty plea - on one violation of the FD&C Act, for misbranding - along with a five-year Corporate Integrity Agreement.
 

Company news: Novartis and Boehringer Ingelheim

May 03, 2012

Novartis said Thursday that generics subsidiary Sandoz is purchasing Fougera Pharmaceuticals for $1.5 billion in cash. In other news, Boehringer Ingelheim launched what it called the largest observational study of non-valvular atrial fibrillation patients.
 

Company news: Elsevier and Eli Lilly

May 02, 2012

Elsevier took over as publisher of The American Journal of Geriatric Psychiatry. In other news, Eli Lilly opened its new Erl Wood research facility Monday.
 

Company news: Biogen Idec and Targacept

May 01, 2012

Biogen Idec reported $975 million in product sales for the quarter ended March 31, up 7.5% compared to sales for the same period last year. In other news, Targacept and AstraZeneca have officially parted ways over the experimental anti-depressant drug known as TC-5214, according to a report.
 

Company news: Amgen and Merck

April 30, 2012

The FDA, as expected, told Amgen that it could not OK the biotech's request to expand the approval for Xgeva into pre-metastases bone cancer, Amgen said.
 

Company news: BMS, Shire, Walgreen

April 26, 2012

Better than expected US sales of Plavix helped Bristol-Myers Squibb power through the first quarter with a 5% revenue gain over the first quarter of 2011, while Shire announced quarter product sales of $1.1 billion for the quarter, a 24% increase over the year-ago period. A Walgreen Co. study shows that discount prescription programs and pharmacists can have a major impact on keeping patients on their medication regimens.
 

Company news: Eli Lilly and GlaxoSmithKline

April 25, 2012

Despite plummeting Zyprexa sales and a forecast of tough times yet to come, Eli Lilly remained upbeat during Wednesday's first-quarter earnings call. Meanwhile, GlaxoSmithKline's CEO Andrew Witty said Wednesday that the $10.5 billion in sales his firm earned for the first quarter of 2012, a 2% bump over the same period last year, is a sign that the company's progress is on track.
 

Company news: GSK, Novartis and Boehringer Ingelheim

April 24, 2012

GlaxoSmithKline continues to shed businesses, but can't shake its weight-loss drug Alli (orlistat).
 

Company news: Abbott; Amylin

April 23, 2012

Abbott Laboratories announced Monday it was expanding its relationship with St. Jude Medical. The new agreement expands on a 2008 partnership.
 

Company news: Cancer Research UK, the Generic Pharmaceutical Association

April 19, 2012

A genetic study of breast cancer has found ten distinct types of the disease and ferreted out "a slew" of previously unknown genetic factors that influence the cancer's aggressiveness.
 

Company news: Abbott, Pfizer, Bristol-Myers Squibb

April 18, 2012

Abbott Laboratories announced Wednesday that sales hit $9.5 billion for the quarter ended March 31, a 4.6% increase over the same period last year. Meanwhile, Pfizer's move to separate itself from its nutrition business is rumored to be gaining momentum and the pharmaceutical industry landed two spots on CR Magazine's list of top corporate citizens, with BMS earning top marks.
 
 Subscribe to the RSS for this page  [view all our RSS feeds here]

Video Exclusive

Web Exclusives

Five industry experts advise specialty pharma company on digital strategy

April 20, 2012

Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.
 

MM&M Awards 2011 HIghlights

The Best MM&M Awards Ever!

MAHF Ceremony 2012

Photos from the Medical Advertising Hall of Fame Awards ceremony